Search Results

open access

The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents

Description: This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
Date: October 9, 2003
Creator: Schacht, Wendy H. & Thomas, John R.
Partner: UNT Libraries Government Documents Department
open access

The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents

Description: This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
Date: September 17, 2003
Creator: Schacht, Wendy H. & Thomas, John R.
Partner: UNT Libraries Government Documents Department
open access

The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents

Description: This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
Date: July 15, 2003
Creator: Schacht, Wendy H. & Thomas, John R.
Partner: UNT Libraries Government Documents Department
open access

The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents

Description: This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
Date: June 30, 2003
Creator: Schacht, Wendy H. & Thomas, John R.
Partner: UNT Libraries Government Documents Department
open access

The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents

Description: This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
Date: June 23, 2003
Creator: Schacht, Wendy H. & Thomas, John R.
Partner: UNT Libraries Government Documents Department
open access

The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents

Description: This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on the Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
Date: May 8, 2003
Creator: Schacht, Wendy H. & Thomas, John R.
Partner: UNT Libraries Government Documents Department
open access

The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents

Description: This record provides information about The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents. Congressional interests in the cost of Pharmaceuticals have focused attention on several areas where the federal government has policies and programs.
Date: January 16, 2003
Creator: Schacht, Wendy H. & Thomas, John R.
Partner: UNT Libraries Government Documents Department
open access

The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents

Description: This record provides information about The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents. Congressional interests in the cost of Pharmaceuticals have focused attention on several areas where the federal government has policies and programs.
Date: November 25, 2002
Creator: Schacht, Wendy H. & Thomas, John R.
Partner: UNT Libraries Government Documents Department
open access

Medical Records Privacy: Questions and Answers on the HIPAA Final Rule

Description: This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Date: March 10, 2004
Creator: Redhead, C. Stephen
Partner: UNT Libraries Government Documents Department
open access

Medical Records Privacy: Questions and Answers on the HIPAA Final Rule

Description: This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Date: June 11, 2003
Creator: Redhead, C. Stephen
Partner: UNT Libraries Government Documents Department
open access

Medical Records Privacy: Questions and Answers on the HIPAA Final Rule

Description: This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Date: January 3, 2003
Creator: Redhead, C. Stephen
Partner: UNT Libraries Government Documents Department
open access

Medical Records Privacy: Questions and Answers on the HIPAA Final Rule

Description: This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Date: October 3, 2002
Creator: Redhead, C. Stephen
Partner: UNT Libraries Government Documents Department
open access

Medical Records Privacy: Questions and Answers on the HIPAA Final Rule

Description: This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Date: September 10, 2001
Creator: Redhead, C. Stephen
Partner: UNT Libraries Government Documents Department
open access

Tobacco Master Settlement Agreement (1998): Overview, Implementation by States, and Congressional Issues

Description: On November 23, 1998, attorneys general representing 46 states, the District of Columbia, and the five U.S. territories signed an agreement with the major cigarette companies to settle all the state lawsuits seeking to recover the Medicaid costs of treating smokers. The Master Settlement Agreement, or MSA, contractually imposes some restrictions on tobacco advertising, marketing, and promotion and requires the manufacturers to make annual payments totaling about $206 billion through 2025. It fo… more
Date: November 5, 1999
Creator: Redhead, C. Stephen
Partner: UNT Libraries Government Documents Department
open access

The Tobacco Settlement: Issues

Description: Since 1994, 41 states and Puerto Rico have sued the tobacco industry to recover the medical costs of treating smokers. On June 20, 1997, a group of state attorneys general and industry lawyers announced that they had reached a settlement that would protect the tobacco companies from civil liability in return for annual industry payments of $365.5 billion over 25 years to reimburse states for their tobacco-related medical costs, and pay for tobacco control programs to reduce tobacco use among te… more
Date: October 16, 1998
Creator: Redhead, C. Stephen
Partner: UNT Libraries Government Documents Department
open access

Compensating Farmers for the Tobacco Settlement

Description: The legislative proposals designed to reduce smoking, primarily by teenagers, are likely to have negative economic consequences for tobacco growers and tobacco-dependent communities. This report discusses the possibility of some kind of compensation to farmers as part of the settlement package legislation.
Date: July 6, 1998
Creator: Womach, Jasper
Partner: UNT Libraries Government Documents Department
open access

The Tobacco Settlement: An Overview

Description: On June 20, a group of state attorneys general, plaintiffs' lawyers, public health advocates, and lawyers representing cigarette manufacturers announced an historic settlement that would restructure the tobacco industry and revolutionize the nation's tobacco control efforts. The proposed settlement is currently under congressional consideration, and would require legislation and the President's approval before taking effect
Date: July 31, 1997
Creator: Redhead, C. Stephen
Partner: UNT Libraries Government Documents Department
open access

Federal R&D, Drug Discovery, and Pricing: Insights from the NIH-University-Industry Relationship

Description: Interest in methods to provide drugs at lower cost, particularly for the elderly, has rekindled discussion over the role the federal government plays in facilitating the creation of new pharmaceuticals for the marketplace. This report explores the issue of whether or not the substantial federal investment in health-related research and development (R&D) entitles the public to commensurate consideration in prices charged for any resulting drugs. It is intended to provide the reader with an under… more
Date: June 19, 2000
Creator: Schacht, Wendy H.
Partner: UNT Libraries Government Documents Department
Back to Top of Screen